DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
Researchers at National Jewish Health and their colleagues have identified structural and molecular markers in the skin of atopic dermatitis patients that distinguish those who have food allergies from those who do not. The findings strengthen emerging science indicating that the skin plays a major role in food allergies, and suggest that personalized treatments for a subset of atopic dermatitis patients might help prevent food allergies.
Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of PeanutAllergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, February 13th, at 4:30 ET / 22:30 CET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
DBV Technologies today announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. DBV is currently working closely with the agency to resubmit the application for Viaskin Peanut as quickly as possible.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically-available Wholesale Acquisition Cost (WAC)2
People with food allergies know eating at a restaurant means using multiple strategies to make sure your order doesn’t contain something that could send you to the hospital with anaphylaxis – a severe life-threatening reaction.
The final research results for a new treatment for protection against accidental exposure to peanut was presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine. The results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.
Although parents often focus on peanuts as the food allergy they need to worry about most, cow’s milk is the most common food allergy in children under the age of 5. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found that over two percent of all U.S. children under the age of 5 have a milk allergy, and 53 percent of food-allergic infants under age 1 have a cow’s milk allergy.
If you are one of the millions of people in the U.S. who has a severe allergy and carries an epinephrine auto injector (EAI) you may have wondered if it will still work if it gets left in your car in winter and freezes. Turns out it will still work, according to new research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.
If the thought of sucking your baby’s pacifier to clean it and then popping it in your baby’s mouth grosses you out, think again. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting suggests a link between parental sucking on a pacifier and a lower allergic response among young children.
FDA is alerting patients, caregivers and health care professionals that the labels attached to some EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, and the authorized generic versions, may block access to the auto-injector and prevent the ability to easily access the product.
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
DBV Technologies today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company’s lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
This Halloween across America, teal pumpkins will signal safe treats for trick-or-treaters with food allergies as part of the Teal Pumpkin Project, an awareness initiative jointly supported this year by Food Allergy Research & Education (FARE), the Asthma and Allergy Foundation of America and several other groups.